BeOne Medicines
ONC
#531
Rank
A$68.57 B
Marketcap
A$600.31
Share price
-0.97%
Change (1 day)
10.12%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeOne Medicines (ONC)

Earnings in 2026 (TTM): A$1.90 Billion

According to BeOne Medicines's latest financial reports the company's current earnings are A$6.60 Billion. In 2025 the company made an earning of A$0.76 Billion, an increase over its 2024 earnings that were of -A$0.86 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeOne Medicines from 2015 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$1.90 B147.28%
2025 A$0.76 B-190.1%
2024 -A$0.86 Billion-52.95%
2023 -A$1.82 Billion-32.52%
2022 -A$2.69 Billion24.39%
2021 -A$2.17 Billion-13.21%
2020 -A$2.49 Billion72.69%
2019 -A$1.45 Billion36.01%
2018 -A$1.06 Billion616.83%
2017 -A$0.15 Billion-15.24%
2016 -A$0.18 Billion107.91%
2015 -A$83.92 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
OPKO Health
OPK
-A$0.24 Billion-112.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
-A$27.27 Million-101.39%๐Ÿ‡บ๐Ÿ‡ธ USA